FDA Authorizes First Vaccine for Respiratory Syncytial Virus (RSV) to Protect Infants and Elders

The US Food and Drug Administration (FDA) has authorized its first vaccine for respiratory syncytial virus (RSV), a common respiratory virus that can lead to fatal consequences for infants or elders. The vaccine, called Arexvy and developed by GlaxoSmithKline (GSK), is approved for those 60 or older and has an efficiency rate of 82.6% in preventing confirmed lower respiratory tract illness brought on by RSV, according to results from a phase 3 clinical investigation. 

The Centers for Disease Control and Prevention (CDC) must support immunizations before the vaccine is pushed into the market, and the Advisory Committee on Immunization Practices (APIC) is expected to approve it during its June 21 to 22 meeting. The FDA is also expected to approve a vaccine for infants under six months of age later this year, and a Sanofi-marketed antibody therapy is also expected to receive clearance soon. RSV is the second most common cause of death for young children worldwide after malaria.

While there is no cure for RSV infection, the symptoms generally improve independently. However, it is crucial to seek advice from a medical professional if symptoms persist, along with staying hydrated and getting good rest.